[Clinical trial of domestic drug polyoxidonium in secondary immunodeficiency].

AIM

To test clinical efficiency and immunocorrectives characteristics of polyoxidonium in patients with chronic bronchitis (CB) and chronic recurrent furunculosis.

MATERIALS AND METHODS

56 patients entered the trial; 13 with CB in remission, 22 with CB in exacerbation and 21 with chronic recurrent furunculosis. Clinical examinations and tests were made before polyoxidonium therapy and 2-3 days after it. Immunological tests consisted of determination of sub-population composition of peripheral blood lymphocytes, serum immunoglobulins and phagocytic activity of neutrophils.

RESULTS

Polyoxidonium is an effective and safe immunocorrector. It has a strong influence on functional activity of blood phagocytic cells.

CONCLUSION

Polyoxidonium treatment of CB and chronic recurrent furunculosis results in positive shifts in hematological and immunological indices. This allows to recommend it for treatment of acute and chronic infections.